Fig. 3From: Impact of a reimbursement policy change on treatment with erenumab in migraine – a real-world experience from GermanyChange in MHD a and MMD b from baseline at first, second and third month of treatment. The asterisk (*) is used to indicate P < 0.05. MHD: monthly headache days, MMD: monthly migraine days. Error bars represent 95% confidence intervalsBack to article page